CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 303 enrolled
Drug / intervention
Erlotinib +1 moredrug
Likely dose
Erlotinib 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00402779
NCT00402779Phase 3Completed
CompareCT.gov

Erlotinib Prevention of Oral Cancer (EPOC)

M.D. Anderson Cancer Center·interventional·Posted Nov 22, 2006·Updated Apr 21, 2020

In Brief

A Phase 3 clinical trial evaluating Erlotinib and Placebo for Oral Cancer. Completed, enrolled 303 participants across 4 sites.

Detailed Summary

The goal of this clinical research study is to learn if erlotinib hydrochloride (Tarcevaâ (OSI-774 ) can prevent cancer in the mouth of people with a high risk of developing cancer in the mouth. The safety of this drug will also be studied, as well as the drug's effect on different cells in the body.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOral Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI), Astellas Pharma US, Inc.

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 22, 2006
Enrollment StartNov 3, 2006
Primary CompletionJun 4, 2018
TodayJul 2, 2026
Enrollment to primary: 11.6 yearsPosted 19.6 years ago

Interventions

Erlotinibdrug

150 mg by mouth daily

Placebodrug

Tablet by mouth daily